AHMED TARANISSI: Open Payments
NPI 1215978689 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$65,652 in 252 payments from 15 companies in 2025. Trend: 2023 $46,736 · 2024 $59,292 · 2025 $65,652
Speaker / faculty: $38,960Honoraria: $10,450Consulting: $9,700Food & beverage: $4,465Travel & lodging: $2,069Education: $9
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 54 | $23,689 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $20,667 |
| Axsome Therapeutics, Inc. | 22 | $10,998 |
| Alkermes, Inc. | 39 | $8,440 |
| Janssen Pharmaceuticals, Inc | 15 | $343 |
| ABBVIE INC. | 18 | $311 |
| Teva Pharmaceuticals USA, Inc. | 17 | $296 |
| Otsuka America Pharmaceutical, Inc. | 21 | $239 |
| Vanda Pharmaceuticals Inc. | 11 | $182 |
| E.R. Squibb & Sons, L.L.C. | 10 | $148 |
Products named: INGREZZA, CAPLYTA, Auvelity, LYBALVI, INVEGA SUSTENNA, VRAYLAR, UZEDY, ARISTADA.
Industry payments across MO — which companies pay providers there.
